Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 11Sarcoma 3Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Neoplasms 1Melanoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1Inflammatory Breast Neoplasms 1HR Positive HER2 Negative Advanced Breast Cancer 1HER-2 Positive Breast Cancer 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

Temozolomide 8Irinotecan 7Vincristine 6Nivolumab 2temsirolimus 1talazoparib 1surufatinib 1sonidegib 1silmitasertib 1regorafenib 1prexasertib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1lenvatinib 1lentiviral minigene vaccine of COVID-19 coronavirus 1irinotecan sucrosofate 1holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid) 1ganitumab 1eribulin 1efineptakin alfa 1dostarlimab 1dinutuximab 1copanlisib 1bempegaldesleukin 1atezolizumab 1adavosertib 1abemaciclib 1Zoledronic Acid 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rhabdomyosarcoma × eribulin × Clear all
NCT03245450 2022-06-28

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Eisai Inc.

Phase 1/2 Completed
40 enrolled 30 charts
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡